

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Broncus Holding Corporation**

**筵博医疗控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2216)**

## **VOLUNTARY ANNOUNCEMENT**

# **BRONCUS'S DISPOSABLE NEBULIZING MICRO-CATHETER FOR ENDOSCOPE WAS APPROVED FOR MARKETING IN CHINA AND ITS APPLICATIONS IN DRUG-DEVICE COMBINATION WILL BE BROADENED**

This announcement is made by Broncus Holding Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and the potential investors of the latest updates of the business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on October 28, 2022, the Company’s innovative product in the field of drug-device combination, “Mist Fountain™” (the “**Product**” or “**Nebulizing Micro-Catheter**”), a disposable nebulizing micro-catheter for endoscope, has been officially approved for marketing by Zhejiang Medical Products Administration (浙江省藥品監督管理局). Currently, the Product is the only nebulizing micro-catheter product on the market which is approved and also protected by multiple patents in China. Its application spans across multiple indications and can be compatible with a variety of drugs, broadening the application of drug-device combination in the field of lung disease treatment.

The Product is used in conjunction with an endoscope to accurately reach the lesion under the guidance of a navigation system, and is used for lavage and spraying of liquid medicine or with a radiocontrast agent. The patented microfluidic chip at the tip of the Nebulizing Micro-catheter, with high-pressure infusion, can reduce the particle size of the drug to mist particles of 20 micrometers ( $\mu\text{m}$ ), and the drug can be in direct contact with local lesions. The drug distribution can be more uniform and the local drug concentration can be significantly increased, thereby directly enhancing the treatment effect. The catheter itself is made of safe materials with high drug compatibility and can be used to adapt to a variety of drugs. Its blunt-rounded front-end design allows doctors to smoothly slide the Product in and protect the bronchial wall during operation, reducing the risk of tissue damage.

The Company has been researching interventional pulmonary devices for years, and the Nebulizing Micro-catheter is the first achievement of the Company in the field of drug-device combination. In the future, the Company will cooperate with clinical experts and biopharmaceutical enterprises to promote, amongst others, the possible application of the Nebulizing Micro-catheter in the anesthesia of bronchoscopy surgery, tuberculosis treatment, targeted drug delivery for oncology. In addition, the Company will continue to explore possible usage scenarios of the Product to cover a wider range of lung disease treatments in order to consolidate leading advantages of the Company in the field of precision interventional diagnosis and treatment of pulmonary diseases.

## INFORMATION ON THE COMPANY

The Company is a pioneer in the interventional pulmonology medical device market, provides innovative lung solutions in China and globally. Founded in 2012, the Company has assembled a management team with extensive experience in product development, clinical research and commercialization, and has developed into an enterprise with a China-US dual center. Through close ties with key opinion leaders in the global respiratory interventional field and the establishment of a comprehensive relationship from innovative concepts to project development and implementation, the Company has built a respiratory interventional diagnosis and treatment product pipeline comprises of 18 products and major product candidates, and owned a diversified intellectual property portfolio of 702 patents and patent applications. In addition, the Company through clinical training and market education and with its strong brand promotion and commercialization capabilities, has sales to mainstream markets around the world such as the United States, Europe, and Australia. The Company's mission is to become a transformative global leader in pulmonology treatment and set its interventional pulmonology diagnosis and treatment solutions as the gold standard.

**Cautionary Statement:** There is no assurance that the Product will ultimately be successfully marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Broncus Holding Corporation**  
**ZHAO Michael Yi Wei**  
*Chairman*

Hong Kong, October 31, 2022

*As at the date of this announcement, the Board comprises Mr. ZHAN Guowei and Mr. XU Hong as executive Directors; Mr. ZHAO Michael Yi Wei as Chairman and non-executive Director; Mr. ZI Zhenjun and Mr. ZHANG Ao as non-executive Directors; and Dr. KAM Pok Man, Professor LAU Joseph Wan Yee and Ms. Wong Yee Sin as independent non-executive Directors.*